Nivolumab

SUSPENDED · PHASE1 · Metastatic Soft-tissue Sarcoma

Protocol amendment

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.